CVRx Faces Securities Investigation After 59% Stock Collapse

The legal scrutiny centers on whether CVRx misled shareholders regarding the stability of its commercial sales force and its reimbursement landscape. On August 6, 2026, the company revealed it had received a Civil Investigative Demand from the Department of Justice back in May. Investigators are examining whether the firm improperly marketed its neuromodulation device or engaged in illegal kickbacks to healthcare providers.

Operational failures compounded the legal pressure. While the company previously touted a $10.5 billion market opportunity and a successful sales force transformation, it recently slashed its 2026 revenue guidance, citing stagnant territory growth and onboarding struggles. Furthermore, the company’s primary Medicare Advantage payer drastically shifted its approval metrics, with 30-day authorization rates plummeting from 80% to 25%. Following the stock price crash on August 7, CVRx terminated Chief Revenue Officer Robert John. Reed Kathrein, the Hagens Berman partner leading the investigation, stated the firm is examining a potential link between the DOJ inquiry and the executive's abrupt departure.